Amgen's (AMGN) Market Perform Rating Reiterated at Leerink Swann

Amgen's (AMGN) Market Perform Rating Reiterated at Leerink Swann


's stock had its "market perform" rating restated by equities research analysts at Leerink Swann in a research report issued to clients and investors on Friday. They presently have a $201.00 target price on the medical research company's stock.



from Biotech News